Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

Le-Vel, the world leader in premium nutrition and lifestyle products, has generously donated approximately 64,000 of its meal ...

On October 14, 2024, MRK announced a clinical development collaboration with Exelixis to evaluate the investigational drug ...

Treatment with belzutifan (Welireg) showed significant benefits over everolimus (Afinitor) for advanced RCC, enhancing PFS and objective response rate (ORR). However, the LITESPARK-005 trial ...

In December 2023, the FDA approved the first HIF2α-directed therapy belzutifan (Welireg) for patients with advanced RCC following a PD-(L)1 inhibitor and a VEGF TKI. 2 NKT2152 is a potent, selective ...

Cabometyx, which is firmly established in the kidney cancer market, is expected to face limited growth opportunities moving forward, particularly due to emerging competition from drugs like Welireg.